Stereotaxis Q1 revenue $7.5M (+9% YoY); recurring up 29%; operating loss widens to $5.9M

Stereotaxis, Inc.

2025-Q1 EPS reported -$0.07 revenue$7,472,000

Revenue $7.5M (+9% YoY); system revenue $2.0M, recurring revenue $5.5M (+29% driven by Map-iT catheters).
Operating loss ($5.9M) vs ($4.7M) prior year; net loss ($5.8M) vs ($4.5M). Adjusted operating loss ($2.7M).
Cash $10.7M, no debt; free cash flow negative ($1.8M), improved from ($2.3M) YoY.
Reiterates FY 2025 double-digit revenue growth; expects recurring revenue to scale to $7M in Q4.
First GenesisX order received; initial MAGiC commercialization in Europe; six active regulatory reviews.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.